Evidence map›Paper›PMID 35092629›Full record

ArticleEuropean journal of immunology2022

Initial properdin binding contributes to alternative pathway activation at the surface of viable and necrotic cells.

Mieke F van Essen, Nicole Schlagwein, Elisa M P van den Hoven, Daniëlle J van Gijlswijk-Janssen, Rosalie Lubbers, Ramon M van den Bos, Jacob van den Born, Jurjen M Ruben, Leendert A Trouw, Cees van Kooten and 1 more

Open access · hybridAbstract read
In one paragraph

Article in European journal of immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Mieke F van EssenDivision of Nephrology and Transplant Medicine, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-1370-2963
Nicole SchlagweinDivision of Nephrology and Transplant Medicine, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Elisa M P van den HovenDivision of Nephrology and Transplant Medicine, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Daniëlle J van Gijlswijk-JanssenDivision of Nephrology and Transplant Medicine, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Rosalie LubbersDepartment of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.
Ramon M van den BosFaculty of Science, Department of Chemistry, Crystal and Structural Chemistry, Bijvoet Center for Biomolecular Research, Utrecht University, Utrecht, The Netherlands.
Jacob van den BornDepartment of Nephrology, University Medical Center Groningen, Groningen, The Netherlands.
Jurjen M RubenDivision of Nephrology and Transplant Medicine, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Leendert A TrouwDepartment of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.
Cees van KootenDivision of Nephrology and Transplant Medicine, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands.
COMBAT consortiumDivision of Nephrology and Transplant Medicine, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Leiden University Medical Center · NLUniversity Medical Center Groningen · NLUniversity of Applied Sciences Utrecht · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Properdin, the only known positive regulator of the complement system, stabilizes the C3 convertase, thereby increasing its half-life. In contrast to most other complement factors, properdin is mainly produced extrahepatically by myeloid cells. Recent data suggest a role for properdin as a pattern recognition molecule. Here, we confirmed previous findings of properdin binding to different necrotic cells including Jurkat T cells. Binding can occur independent of C3, as demonstrated by HAP-1 C3 KO cells, excluding a role for endogenous C3. In view of the cellular source of properdin, interaction with myeloid cells was examined. Properdin bound to the surface of viable monocyte-derived pro- and anti-inflammatory macrophages, but not to DCs. Binding was demonstrated for purified properdin as well as fractionated P2, P3, and P4 properdin oligomers. Binding contributed to local complement activation as determined by C3 and C5b-9 deposition on the cell surfaces and seems a prerequisite for alternative pathway activation. Interaction of properdin with cell surfaces could be inhibited with the tick protein Salp20 and by different polysaccharides, depending on sulfation and chain length. These data identify properdin as a factor interacting with different cell surfaces, being either dead or alive, contributing to the local stimulation of complement activation.

Indexed as

Complement C3-C5 ConvertasesProperdinComplement ActivationComplement Membrane Attack ComplexComplement Pathway, AlternativeHumansNecrosisComplement C3-C5 ConvertasesComplement Membrane Attack ComplexProperdinAlternative pathwayComplement systemDendritic cellsMacrophagesProperdinViable/death cells

Identifiers

PMID35092629
PMCPMC9303752
OpenAlexW4210525865

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.